obudanersen

DRUG2 trials

Sponsors

Ionis Pharmaceuticals, Inc.

Conditions

Angelman Syndrome

Phase 3

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

RecruitingNCT06914609

Ionis Pharmaceuticals, Inc.Angelman Syndrome

Start: 2025-06-10End: 2030-04-01Target: 158Updated: 2026-08-28

CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)

Not yet recruitingNCT07782827

Ionis Pharmaceuticals, Inc.Angelman Syndrome

Start: 2026-09-01End: 2031-05-01Target: 30Updated: 2026-08-24